Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M32,857Revenue (TTM) $M2,705Net Margin (%)5.4Altman Z-Score4.7
Enterprise Value $M35,251EPS (TTM) $0.7Operating Margin %22.1Piotroski F-Score4
P/E(ttm)204Beneish M-Score-2.1Pre-tax Margin (%)19.8Higher ROA y-yN
Price/Book4.110-y EBITDA Growth Rate %--Quick Ratio3.0Cash flow > EarningsY
Price/Sales11.85-y EBITDA Growth Rate %35.4Current Ratio3.5Lower Leverage y-yN
Price/Free Cash Flow60.5y-y EBITDA Growth Rate %-3.3ROA % (ttm)1.3Higher Current Ratio y-yN
Dividend Yield %--PEG5.6ROE % (ttm)2.0Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M224ROIC % (ttm)1.9Gross Margin Increase y-yY

Gurus Latest Trades with ALXN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ALXNJohn Paulson 2016-03-31 Buy 0.17%$127.91 - $190.75
($147.61)
$ 146.67-1%New holding157,200
ALXNJoel Greenblatt 2016-03-31 Buy 0.02%$127.91 - $190.75
($147.61)
$ 146.67-1%New holding10,684
ALXNRon Baron 2016-03-31 Reduce$127.91 - $190.75
($147.61)
$ 146.67-1%Reduce -8.54%55,950
ALXNDodge & Cox 2016-03-31 Buy $127.91 - $190.75
($147.61)
$ 146.67-1%New holding1,820
ALXNRon Baron 2015-12-31 Add0.02%$152.66 - $191.88
($175.28)
$ 146.67-16%Add 87.52%61,177
ALXNDavid Swensen 2015-09-30 Sold Out -16.37%$145.6 - $207.84
($182.41)
$ 146.67-20%Sold Out0
ALXNRon Baron 2015-09-30 Reduce-0.03%$145.6 - $207.84
($182.41)
$ 146.67-20%Reduce -53.24%32,624
ALXNMario Gabelli 2015-09-30 Sold Out $145.6 - $207.84
($182.41)
$ 146.67-20%Sold Out0
ALXNDavid Swensen 2015-06-30 Buy 16.37%$155.01 - $190.92
($172.58)
$ 146.67-15%New holding319,273
ALXNJoel Greenblatt 2015-06-30 Sold Out -0.03%$155.01 - $190.92
($172.58)
$ 146.67-15%Sold Out0
ALXNRon Baron 2015-06-30 Add0.02%$155.01 - $190.92
($172.58)
$ 146.67-15%Add 69.48%69,764
ALXNMario Gabelli 2015-06-30 Buy $155.01 - $190.92
($172.58)
$ 146.67-15%New holding1,415
ALXNJoel Greenblatt 2015-03-31 Reduce-0.09%$171.42 - $189.07
($181.01)
$ 146.67-19%Reduce -72.94%23,261
ALXNRon Baron 2015-03-31 Add0.02%$171.42 - $189.07
($181.01)
$ 146.67-19%Add 124.13%41,163
ALXNJoel Greenblatt 2014-12-31 Add0.13%$159.46 - $200.79
($185.68)
$ 146.67-21%Add 4665.74%85,974
ALXNRon Baron 2014-12-31 Add$159.46 - $200.79
($185.68)
$ 146.67-21%Add 41.92%18,366
ALXNJoel Greenblatt 2014-09-30 Reduce-0.03%$155.06 - $173.08
($164.22)
$ 146.67-11%Reduce -89.45%1,804
ALXNRon Baron 2014-09-30 Add$155.06 - $173.08
($164.22)
$ 146.67-11%Add 27.56%12,941
ALXNJoel Greenblatt 2014-06-30 Add0.02%$139.61 - $170.2
($157.93)
$ 146.67-7%Add 240.11%17,094
ALXNJoel Greenblatt 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 146.67-7%New holding5,026
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ALXN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ALXN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
MACKAY MARTINEVP & Global Head of R&D 2016-05-16Sell4,097$139.22.38view
Wagner Heidi LSVP, Global Government Affairs 2016-05-13Sell53$138.652.78view
Hallal DavidCEO 2016-04-01Sell1,414$135.884.88view
O'Neill JulieEVP. Global Operations 2016-03-02Sell651$149.55-4.71view
Wagner Heidi LSVP, Global Government Affairs 2016-02-29Sell547$138.912.59view
Thiel CarstenEVP, Chief Commercial Officer 2016-02-29Sell54$138.912.59view
MACKAY MARTINEVP & Global Head of R&D 2016-02-29Sell1,000$138.912.59view
Miller EdwardSVP, Chief Compliance Officer 2016-02-29Sell329$138.912.59view
Islam SaqibEVP, Chief Strat & Port. Off. 2016-02-29Sell905$138.912.59view
Sinha VikasEVP & CFO 2016-02-29Sell1,122$138.912.59view

Quarterly/Annual Reports about ALXN:

News about ALXN:

Articles On GuruFocus.com
Baron Funds Comments on Alexion Pharmaceuticals May 23 2016 
Baron Funds Comments on Alexion Pharmaceuticals May 23 2016 
Baron Funds Comments on Alexion Pharmaceuticals May 06 2016 
Baron Funds Comments on Alexion Pharmaceuticals Feb 08 2016 
Weekly CFO Sales Highlight: H&R Block, DISH Network, Alexion Pharmaceuticals Jan 03 2016 
Weekly CFO Sells Highlight: Tyson Foods, Alexion Pharmaceuticals, Gilead Sciences Dec 13 2015 
Weekly Insider Sells Highlights: CDW, Twitter, P&G, Alexion Pharmaceuticals Dec 10 2015 
Alexion Pharmaceuticals Loses Position in Swensen's Portfolio Dec 03 2015 
Jim Simons' Largest Adds of the 3rd Quarter Nov 13 2015 
Baron Funds Comments on Alexion Pharmaceuticals Inc. Nov 10 2015 

More From Other Websites
Interest Rate Concerns Lead to Market Losses: How Did XLV React? May 19 2016
Researchers to Present Late-Breaking Data on ALXN1210 in Patients with PNH at EHA Annual Congress May 19 2016
Researchers to Present Late-Breaking Data on ALXN1210 in Patients with PNH at EHA Annual Congress May 19 2016
ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 16 2016
Inside Alexion’s Metabolic Drugs Kanuma and Strensiq May 16 2016
5 Big Blue-Chip Stocks to Buy for Breakout Gains May 12 2016
Alexion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ALXN-US : May... May 11 2016
Trending Now: ALXN May 10 2016
Mutual Fund Redemptions Are A Headwind For These Large-Cap Stocks May 06 2016
ALEXION PHARMACEUTICALS INC Financials May 05 2016
How Much Upside Potential Does Alexion Have? May 05 2016
Inside Soliris’s Continued Growth Momentum May 04 2016
Alexion to Present at the Bank of America Merrill Lynch 2016 Health Care Conference May 04 2016
Alexion to Present at the Bank of America Merrill Lynch 2016 Health Care Conference May 04 2016
Understanding Alexion’s Share Price Performance since Its Previous Earnings May 03 2016
How Wall Street Feels about Alexion’s 1Q16 Earnings May 03 2016
Biotech ETFs Sink on Mixed Q1 Results May 02 2016
Alexion Pharmaceuticals, Inc. :ALXN-US: Earnings Analysis: Q1, 2016 By the Numbers May 02 2016
Analysts Make Major Changes to Top Biotech Ratings May 01 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)